🟢 Biomea Fusion is trading 8.1% up in pre-market ahead of scheduled BMF-650 Phase I results

Biomea Fusion is trading at $1.47, up 8.11% pre-market ahead of its planned Phase I results update for BMF-650.

• On October 12, Biomea Fusion announced it would report Phase I results for BMF-650, its investigational oral GLP-1 candidate, on October 13.
• The company scheduled a webcast and conference call for 4:30 p.m. ET; results had not been announced as of 4:10 a.m.
• The shares closed at $1.36 on October 12; no pre-market volume data was provided.